FierceBiotechOriginal article
{"a":[{"_":"Novartis ends ALS program after phase 2 flop, adding to R&D woes","$":{"href":"/biotech/novartis-ends-als-program-after-phase-2-flop-adding-rd-woes","hreflang":"en"}}]}
Phase 2negativeNegative
AI Analysis
Summary
Novartis has terminated an ALS program following a phase 2 trial failure, continuing the company's recent string of R&D setbacks.
Clinical Trial Data
Phase
2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial failure
Importance:6/10
Sentiment:
-0.80
ALSprogram terminationclinical trial failureR&D
Related Companies
Read the original article
Published by FierceBiotech on September 16, 2026 10:28 AM